Brook Nelson, PA
Physician Assistant · Martinsville, VANPI 1366731200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 930 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 930 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Otsuka America Pharmaceutical, Inc.$985
- Pfizer$888
- AstraZeneca$765
- Lilly USA, LLC$721
- plus $7K from 54 others
What the payments were for
- Food & beverage$14,110100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,110 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $149,913 |
| FarxigaDapagliflozin Propanediol | 147 | $134,616 |
| TrulicityDulaglutide | 88 | $88,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $68,312 |
| EliquisApixaban | 68 | $60,535 |
| OtezlaApremilast | 11 | $53,280 |
| MounjaroTirzepatide | 43 | $52,485 |
| JardianceEmpagliflozin | 51 | $51,058 |
| JanuviaSitagliptin Phosphate | 35 | $47,319 |
| RexultiBrexpiprazole | 28 | $40,780 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $39,118 |
| LinzessLinaclotide | 50 | $38,710 |
| XareltoRivaroxaban | 37 | $32,639 |
| VraylarCariprazine Hcl | 13 | $27,044 |
| MyrbetriqMirabegron | 40 | $25,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,275 | $149,913112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $765 | $143,613161 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $721 | $141,424131 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $541 | $83,157137 claims |
| AbbVieLinzess, Vraylar, Synthroid | $2,229 | $68,46194 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $302 | $62,45867 claims |
| MerckJanuvia, Janumet, Belsomra | $328 | $61,27962 claims |
| PfizerEliquis | $888 | $60,53568 claims |
| AmgenOtezla | $603 | $53,28011 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $985 | $40,78028 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $265 | $39,64048 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $80 | $39,11836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Martinsville
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- John CarterStaunton$90K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Robert HigginsonRichmond$66K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
- Juliette BeristainVirginia Beach$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.